A icon

Agilent Technologies

113.77 USD
+1.37
1.22%
At close May 16, 4:00 PM EDT
After hours
113.77
+0.00
0.00%
1 day
1.22%
5 days
2.67%
1 month
10.78%
3 months
-15.85%
6 months
-10.36%
Year to date
-14.73%
1 year
-26.27%
5 years
35.99%
10 years
166.88%
 

About: Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.

Employees: 17,900

0
Funds holding %
of 7,457 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

18% more call options, than puts

Call options by funds: $138M | Put options by funds: $116M

13% more funds holding in top 10

Funds holding in top 10: 8 [Q4 2024] → 9 (+1) [Q1 2025]

2.65% less ownership

Funds ownership: 88.29% [Q4 2024] → 85.64% (-2.65%) [Q1 2025]

7% less funds holding

Funds holding: 1,060 [Q4 2024] → 981 (-79) [Q1 2025]

16% less capital invested

Capital invested by funds: $33.9B [Q4 2024] → $28.5B (-$5.34B) [Q1 2025]

18% less repeat investments, than reductions

Existing positions increased: 323 | Existing positions reduced: 393

34% less first-time investments, than exits

New positions opened: 92 | Existing positions closed: 139

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$115
1%
upside
Avg. target
$131
15%
upside
High target
$159
40%
upside

4 analyst ratings

positive
50%
neutral
50%
negative
0%
Jefferies
Brandon Couillard
8% 1-year accuracy
2 / 25 met price target
2%upside
$116
Hold
Maintained
21 Apr 2025
Wells Fargo
Brandon Couillard
8% 1-year accuracy
2 / 25 met price target
19%upside
$135
Overweight
Maintained
17 Apr 2025
Barclays
Luke Sergott
29% 1-year accuracy
18 / 63 met price target
1%upside
$115
Equal-Weight
Maintained
10 Apr 2025
Baird
Catherine Schulte
11% 1-year accuracy
2 / 18 met price target
40%upside
$159
Outperform
Maintained
27 Feb 2025

Financial journalist opinion

Based on 8 articles about A published over the past 30 days

Neutral
Business Wire
2 days ago
Agilent to Participate in Jefferies Global Healthcare Conference
SANTA CLARA, Calif--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell — along with CFO Bob McMahon — will participate in a fireside chat at the Jefferies Global Healthcare Conference at 10:30 a.m. Eastern on Wednesday, June 4, 2025, in New York City. A live audio webcast and replay of the presentation will be available on the Agilent Investor Relations website. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in anal.
Agilent to Participate in Jefferies Global Healthcare Conference
Positive
Seeking Alpha
1 week ago
Scale Has Its Advantages: 3 A-Rated REIT Monopolies
Scale is a critical competitive advantage for companies, enabling them to expand, attract capital, and achieve strong market positions, as seen with Realty Income, Prologis, and Public Storage. Realty Income leverages its scale and diversification to maintain high occupancy rates and strong financial performance, boasting a fortress balance sheet and impressive dividend growth. Prologis excels with its vast warehouse portfolio, robust development pipeline, and strategic expansion into data centers, supported by a strong balance sheet and high earnings growth.
Scale Has Its Advantages: 3 A-Rated REIT Monopolies
Positive
Zacks Investment Research
2 weeks ago
Will Agilent (A) Beat Estimates Again in Its Next Earnings Report?
Agilent (A) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Agilent (A) Beat Estimates Again in Its Next Earnings Report?
Neutral
Business Wire
2 weeks ago
Agilent Unveils Transformative Seahorse XF Flex Analyzer: Revolutionizing 3D Tissue and Organoid Research
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced release of the new Seahorse XF Flex Analyzer, a high-performance, 24-well system designed to expand real-time metabolic analysis into optimized 3D tissue and organoid workflows, along with dedicated consumables and kit. Metabolism is vital for cellular functions, driving energy production and essential processes such as biosynthesis, adaptation, redox balance, mitochondrial function, and cell fate decision.
Agilent Unveils Transformative Seahorse XF Flex Analyzer: Revolutionizing 3D Tissue and Organoid Research
Positive
Zacks Investment Research
2 weeks ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Positive
Seeking Alpha
3 weeks ago
City Office REIT (RED PFD SER A): A High Yield, Deep Value Opportunity Worth Latching Onto
City Office REIT's Series A Preferred Shares offer a tempting yield despite recent accounting losses and systemic pressures, suggesting a potential buying opportunity. The shares are cumulative, redeemable, and fixed, ensuring eventual dividend payments, though call risk and financial restructuring are potential concerns. The REIT's fundamentals, including an 85.8% occupancy rate and sector diversification, support sustainability, with positive economic profitability and AFFO figures.
City Office REIT (RED PFD SER A): A High Yield, Deep Value Opportunity Worth Latching Onto
Neutral
GlobeNewsWire
3 weeks ago
Smackover Lithium's South West Arkansas Project Receives Unanimous Vote of Approval to Establish the Phase I Brine Production Unit from the Arkansas Oil and Gas Commission
LEWISVILLE, Ark., April 24, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture (“JV”) between Standard Lithium Ltd.
Smackover Lithium's South West Arkansas Project Receives Unanimous Vote of Approval to Establish the Phase I Brine Production Unit from the Arkansas Oil and Gas Commission
Neutral
Business Wire
3 weeks ago
Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions t.
Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025
Neutral
Business Wire
1 month ago
Agilent Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with KEYTRUDA® (pembrolizumab)1. PD-L1 IHC 22C3 pharmDx (Code SK006) is approved for exclusive use with the Agilent Autostainer Link 48 advanced.
Agilent Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Positive
Zacks Investment Research
1 month ago
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Charts implemented using Lightweight Charts™